GJC2 and lymphatic system disorder: Whether we will be able to target Cxs for the treatment of lymphatic disorders will very much depend on the unraveling of the effects of the GJC2 and GJA1 gene mutations (and maybe in the future also GJA4 and Panx1 gene mutations) in relevant in vitro, ex vivo and in vivo models.